Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to foundational, pre-competitive discovery technologies and services across six biologic modalities. Keyway™ TCR Discovery is Alloy’s integrated service offering developing protein engineering solutions for targeting pHLA complexes, spanning target selection through to final characterized leads of therapeutic TCR mimics and engineered TCRs.
BioCopy is based in Switzerland and Germany. We focus on drug discovery for immuno-oncological therapeutics. Our unique platform technology enables us to screen TCR(m) interactions vs. thousands of peptide-HLA complexes – label-free in one single experiment.
BioCopys uniquely combines microarray customization, high-throughput binding-kinetics and bioinformatics. We characterize and validate immune responses of TCR(m)-based immuno-oncology drug candidates in our own drug development – and as a service for your drug pipeline!
OmniAb, Inc.’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others. The OmniAb suite of technologies span from BI-powered repertoire generation to cutting edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.
Ardigen enables AI transformation for biotech and pharmaceutical companies to leverage the full potential of data. The company delivers value at the intersection of biology and computational methods to increase the likelihood of success and accelerate the drug discovery process. With our platforms based on advanced algorithms and state-of-the-art technology, we help researchers to get scientific insights from a large amount of data, leading to new discoveries and breakthroughs in personalized medicine and drug development.
For 30 years, Miltenyi Biotec has been dedicated to improving scientific understanding and medical progress for clinical research and cell and gene therapy (CGT). Our products and services facilitate the advancement of science in these key areas, and support clinicians who are bringing new cellular therapies to reality. We specialize in developing tailored cell processing protocols for the fully automated and closed, GMP-compliant CliniMACS Prodigy®. In addition, we offer comprehensive CGT support, including contract development and manufacturing of CGT products and tailored GMP lentiviral vectors.
Alithea Bio (Freiburg, GER) was registered in 2019 and is based on the HLA peptidome research of Tim Fugmann. He had multiple roles in Biotech and academia including a Prof. position for mass spectrometry-based proteomics. Alithea’s mission is to facilitate and accelerate development of peptide HLA-targeted therapeutics such as TCR mimics and TCR T cell therapies. To realize a holistic view on the HLA-presented peptides understanding and guiding immune reactions in individuals, Alithea has created a large HLA peptide database from >3000 samples covering 1.1 Million ligands and their abundance in health and disease. Further, Alithea can readily screen for novel targets and potential on and off-target toxicities.